BioRestorative receives notice of allowance by USPTO for ThermoStem program

BioRestorative Therapies announced that the United States Patent and Trademark Office, USPTO, has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem program. The notice of allowance was issued on February 24, 2023. This will be the third patent granted under this particular family of intellectual property, claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells. "This is the second notice of allowance we have received regarding our ThermoStem program within 2023. This notice of allowance is very meaningful as it provides the Company with further protection and strengthens our technology as we develop and expand into the clinic. Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities" said Lance Alstodt, the Company’s CEO.